Add Yahoo as a preferred source to see more of our stories on Google. In the past month, I’ve talked to four different people who have either had a sinus surgery or an actual sinus fungal ball, so ...

Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...

The FDA approved dupilumab (Dupixent) for treating allergic fungal rhinosinusitis, a first for the condition, the agency announced on Wednesday. Approval stipulates use in individuals 6 years and ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...

Treatment with dupilumab led to significant reductions in sinus opacification, nasal congestion and nasal polyps in patients with allergic fungal rhinosinusitis. Dupilumab, an interleukin-4 receptor ...

Drs. Jessa Miller and Amrita Ray discuss the paradox of increasing incidence and decreasing mortality in AIFRS.

A new research perspective was published in Oncoscience (Volume 10) on May 27, 2023, entitled, "Think outside the box – atypical infections in chronic sinusitis." Inflammations of the paranasal ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a ...